128 Sidney Street
292 articles with Acceleron Pharma
Acceleron Pharma Inc. today announced that it has priced an underwritten public offering of 5,348,838 shares of common stock at a price to the public of $43.00 per share for gross proceeds of $230.0 million.
Acceleron Pharma Inc. (Nasdaq:XLRN), a leading biopharmaceutical company in the discovery and development of TGF-beta superfamily therapeutics to treat serious and rare hematologic, neuromuscular, and pulmonary diseases, today announced that it intends to offer and sell, subject to market and other conditions, $200 million of its common stock in an underwritten public offering.
Acceleron Pharma Inc. today announced that the journal Blood has published results from the Phase 2 study of luspatercept in patients with red blood cell (RBC) transfusion-dependent and non-transfusion-dependent beta-thalassemia.
EvaluatePharma and Vantage recently released their Vantage 2019 Preview which looks at the current year’s biopharma market and makes projections about the upcoming year.
Acceleron Pharma Inc. today announced that Habib Dable, President and Chief Executive Officer, will present an overview of the company along with its upcoming corporate priorities at the 37th Annual J.P. Morgan Healthcare Conference on Monday, January 7, 2019 at 2:00 p.m. PST / 5:00 p.m. EST in San Francisco, California.
With the American Society of Hematology (ASH) Annual Meeting held this weekend, Celgene and its various collaboration partners had several important presentations.
12/3/2018The American Society of Hematology Annual Meeting is always chock full of interesting research and development stories. Here’s a look at some of the highlights of the meeting so far, which is continuing today.
Celgene Corporation and Acceleron Pharma Announce Results of the Phase 3 MEDALIST Trial Evaluating Luspatercept in Patients with Myelodysplastic Syndromes at the ASH 2018 Plenary Session
Pivotal phase 3 data demonstrated treatment with investigational luspatercept resulted in statistically significant increased red blood cell transfusion independence compared to placebo
Celgene Corporation and Acceleron Pharma Announce Results of the Phase 3 BELIEVE Trial Evaluating Luspatercept in Adult Patients with Beta-Thalassemia at ASH 2018
Celgene Corporation (NASDAQ: CELG) and Acceleron Pharma Inc. (NASDAQ: XLRN) today announced results from a pivotal, phase 3 trial (BELIEVE) evaluating the safety and efficacy of luspatercept for the treatment of adults with beta-thalassemia-associated anemia who require regular red blood cell (RBC) transfusions.
Acceleron Pharma Inc. today announced that the United States Food and Drug Administration (FDA) has granted Fast Track designation to ACE-083, the Company’s locally-acting “Myostatin+” muscle agent, for the treatment of patients with Charcot-Marie-Tooth disease (CMT).
Acceleron to Host Conference Call and Webcast to Review MEDALIST and BELIEVE Phase 3 Trial Presentations of Luspatercept at the 60th American Society of Hematology Annual Meeting
Acceleron Pharma Inc. today announced it will host a conference call and live audio webcast on Monday, December 3, 2018 at 9:00 a.m. EST to review the MEDALIST and BELIEVE Phase 3 trial presentations of luspatercept at the 60th American Society of Hematology (ASH) Annual Meeting and Exposition taking place on December 1-4, 2018 in San Diego, California.
Acceleron Pharma Inc. today announced that senior management will participate in two upcoming healthcare investor conferences.
Acceleron Announces Preclinical Presentations on Sotatercept in Pulmonary Arterial Hypertension at the 2018 American Heart Association Scientific Session
Acceleron Pharma Inc. today announced plans to deliver three preclinical presentations on sotatercept in Pulmonary Arterial Hypertension (PAH) at the 2018 American Heart Association (AHA) Scientific Session in Chicago, IL, November 10-12, 2018.
Acceleron Announces that Phase 3 Results from the MEDALIST and BELIEVE Trials of Luspatercept will be Presented at the 60th American Society of Hematology Annual Meeting
Phase 3 MEDALIST trial results to be presented in Plenary Scientific Session
Acceleron Pharma Inc. (Nasdaq:XLRN), a leading biopharmaceutical company in the discovery and development of TGF-beta therapeutics to treat serious and rare diseases, today provided a corporate update and reported financial results for the third quarter ended September 30, 2018.
The webcast will be accessible under "Events & Presentations" in the Investors/Media page of the company's website
Acceleron to Host Pulmonary Arterial Hypertension Research and Development Deep Dive Event on November 16, 2018 in New York City
Live presentation and webcast to be held on November 16th at 9:00 a.m. EST
10/1/2018Here's a look at who shook things up in the world of pharma and biotech this week.
Acceleron to Participate in Three Upcoming September and October 2018 Healthcare Investor Conferences
Acceleron Pharma Inc. today announced that senior management will participate in three upcoming healthcare investor conferences.
MEDALIST and BELIEVE Phase 3 trials met all primary and key secondary endpoint